| 초록 |
Objectives: Presepsin has recently been recognized as a reliable biomarker for sepsis. Nevertheless, there is a paucity of studies specifically focusing on its predictive value for mortality in patients with urinary tract infection (UTI). This study aimed to evaluate the utility of plasma presepsin as a mortality predictor in patients with UTI compared to traditional infection biomarkers. Methods: A single-center retrospective study was conducted from May 2022 to August 2023, enrolling 74 patients with UTI. Collected data at admission included vital signs, plasma presepsin, procalcitonin, C-reactive protein (CRP), white blood cell (WBC) count, and other laboratory values. Predictive values for 28-day mortality of plasma presepsin, procalcitonin, CRP, and WBC were analyzed using receiver operating characteristic (ROC) curve analysis. Multivariate Cox regression analysis was performed on 28-day mortality according to the cut-off values of plasma presepsin, procalcitonin, CRP, and WBC. Results: Plasma presepsin showed a higher area under ROC curve (AuROC) of 0.781 for predicting 28-day mortality, surpassing procalcitonin (AuROC 0.606), CRP (AuROC 0.496), and WBC (AuROC 0.495). Elevated plasma presepsin levels (>831pg/mL) were independently associated with an increased risk of 28-day mortality in patients with UTI (hazard ratio: 8.753, P = 0.041). Conclusions: Presepsin may serve as a significant prognostic biomarker for mortality in patients with UTI, suggesting its superiority over traditional infection biomarkers. |